Previous Article | Next Article ![]()
Journal of Virology, October 2000, p. 9083-9089, Vol. 74, No. 19
Department of Microbiology and
Immunology1 and The Graduate Institute
of Medical Science,2 National Defense Medical
Center, and Institute of Molecular Biology, Academia
Sinica,5 Taipei, and Department of
Ophthalmology, Chang Gung Memorial Hospital and Chang Gung University,
Taoyuan,3 Taiwan, Republic of China, and
Department of Urology, The Southwestern Medical School, Dallas,
Texas4
Received 2 May 2000/Accepted 14 July 2000
The potential of the E5 protein as a tumor vaccine candidate has
not been explored yet. In this study, we evaluate the human papillomavirus type 16 (HPV-16) E5 protein delivered by an adenovirus vector as a tumor vaccine for cervical lesions. The results demonstrate that a single intramuscular injection of a recombinant adenovirus carrying the HPV-16 E5 gene into syngeneic animals can reduce the
growth of tumors which contain E5 gene expression. Moreover, the E5
vaccine-induced tumor protection occurs through CD8 T cells but not
through CD4 T cells in in vitro assays. In addition, our studies using
knockout mice with distinct T-cell deficiencies confirm that cytotoxic
T-lymphocyte-induced tumor protection is CD8 dependent but CD4
independent. Hence, HPV-16 E5 can be regarded as a tumor rejection antigen.
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Induction of CD8 T Cells by Vaccination with Recombinant
Adenovirus Expressing Human Papillomavirus Type 16 E5 Gene Reduces
Tumor Growth
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan, Republic of China. Phone: 886-2-87923100, ext. 18543. Fax:
886-2-87924885. E-mail: yptsao{at}kimo.com.tw.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»